These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31862892)

  • 1. Mesenchymal Stromal Cells Induce Podocyte Protection in the Puromycin Injury Model.
    Ornellas FM; Ramalho RJ; Fanelli C; Garnica MR; Malheiros DMAC; Martini SV; Morales MM; Noronha IL
    Sci Rep; 2019 Dec; 9(1):19604. PubMed ID: 31862892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Differential expressions of miRNAs in kidney in puromycin aminonucleoside nephropathy model and intervened effects of Leizhi capsule].
    Sun W; Li CQ; Chen JH; Shao JD; Zhou D; Zhang L; Gao K
    Zhongguo Zhong Yao Za Zhi; 2013 Jan; 38(1):81-90. PubMed ID: 23596882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.
    Wang S; Li Y; Zhao J; Zhang J; Huang Y
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):538-46. PubMed ID: 23295166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenomedullin ameliorates podocyte injury induced by puromycin aminonucleoside in vitro and in vivo through modulation of Rho GTPases.
    Dong N; Meng L; Xue R; Yu M; Zhao Z; Liu X
    Int Urol Nephrol; 2017 Aug; 49(8):1489-1506. PubMed ID: 28528353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside.
    Ma J; Matsusaka T; Yang HC; Zhong J; Takagi N; Fogo AB; Kon V; Ichikawa I
    Pediatr Res; 2011 Jul; 70(1):83-9. PubMed ID: 21451433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.
    Okada T; Sakaguchi T; Hatamura I; Saji F; Negi S; Otani H; Muragaki Y; Kawachi H; Shigematsu T
    Clin Exp Nephrol; 2009 Oct; 13(5):438-446. PubMed ID: 19452240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GIV/girdin links vascular endothelial growth factor signaling to Akt survival signaling in podocytes independent of nephrin.
    Wang H; Misaki T; Taupin V; Eguchi A; Ghosh P; Farquhar MG
    J Am Soc Nephrol; 2015 Feb; 26(2):314-27. PubMed ID: 25012178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Connective tissue growth factor modulates podocyte actin cytoskeleton and extracellular matrix synthesis and is induced in podocytes upon injury.
    Fuchshofer R; Ullmann S; Zeilbeck LF; Baumann M; Junglas B; Tamm ER
    Histochem Cell Biol; 2011 Sep; 136(3):301-19. PubMed ID: 21814837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NADPH oxidase-derived ROS contributes to upregulation of TRPC6 expression in puromycin aminonucleoside-induced podocyte injury.
    Wang Z; Wei X; Zhang Y; Ma X; Li B; Zhang S; Du P; Zhang X; Yi F
    Cell Physiol Biochem; 2009; 24(5-6):619-26. PubMed ID: 19910702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
    Fukuda A; Fujimoto S; Iwatsubo S; Kawachi H; Kitamura K
    Nephrology (Carlton); 2010 Apr; 15(3):321-6. PubMed ID: 20470301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective Effect of Salvia Przewalskii Extract on Puromycin-Induced Podocyte Injury.
    Dai DS; Liu X; Yang Y; Luo XM; Tang RX; Yin ZC; Ren HQ
    Am J Nephrol; 2015; 42(3):216-27. PubMed ID: 26439819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.
    Chen CA; Hwang JC; Guh JY; Chang JM; Lai YH; Chen HC
    J Lab Clin Med; 2006 Feb; 147(2):74-82. PubMed ID: 16459165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stem cells prevent podocyte injury in lupus-prone B6.MRL-Faslpr mice via polarizing macrophage into an anti-inflammatory phenotype.
    Zhang Z; Niu L; Tang X; Feng R; Yao G; Chen W; Li W; Feng X; Chen H; Sun L
    Nephrol Dial Transplant; 2019 Apr; 34(4):597-605. PubMed ID: 29982691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of microRNA-30 facilitates podocyte injury and is prevented by glucocorticoids.
    Wu J; Zheng C; Fan Y; Zeng C; Chen Z; Qin W; Zhang C; Zhang W; Wang X; Zhu X; Zhang M; Zen K; Liu Z
    J Am Soc Nephrol; 2014 Jan; 25(1):92-104. PubMed ID: 24029422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling.
    Shibata S; Nagase M; Fujita T
    J Am Soc Nephrol; 2006 Mar; 17(3):754-64. PubMed ID: 16452496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.
    Celik Y; Celik F
    Transl Res; 2006 Jul; 148(1):46. PubMed ID: 16887498
    [No Abstract]   [Full Text] [Related]  

  • 17. Podocyte injury is suppressed by 1,25-dihydroxyvitamin D via modulation of transforming growth factor-beta 1/bone morphogenetic protein-7 signalling in puromycin aminonucleoside nephropathy rats.
    Xiao HQ; Shi W; Liu SX; Zhang B; Xu LX; Liang XL; Liang YZ
    Clin Exp Pharmacol Physiol; 2009 Jul; 36(7):682-9. PubMed ID: 19594554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Podocyte autophagic activity plays a protective role in renal injury and delays the progression of podocytopathies.
    Zeng C; Fan Y; Wu J; Shi S; Chen Z; Zhong Y; Zhang C; Zen K; Liu Z
    J Pathol; 2014 Oct; 234(2):203-13. PubMed ID: 24870816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies.
    Eriguchi M; Yotsueda R; Torisu K; Kawai Y; Hasegawa S; Tanaka S; Noguchi H; Masutani K; Kitazono T; Tsuruya K
    Am J Physiol Renal Physiol; 2016 Feb; 310(4):F322-33. PubMed ID: 26632605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro.
    Zheng CX; Chen ZH; Zeng CH; Qin WS; Li LS; Liu ZH
    Kidney Int; 2008 Sep; 74(5):596-612. PubMed ID: 18509322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.